1620 Investment Advisors, Inc. Pacira Bio Sciences, Inc. Transaction History
1620 Investment Advisors, Inc.
- $142 Million
- Q3 2025
A detailed history of 1620 Investment Advisors, Inc. transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, 1620 Investment Advisors, Inc. holds 977 shares of PCRX stock, worth $23,233. This represents 0.02% of its overall portfolio holdings.
Number of Shares
977
Previous 977
-0.0%
Holding current value
$23,233
Previous $23,000
8.7%
% of portfolio
0.02%
Previous 0.02%
Shares
4 transactions
Others Institutions Holding PCRX
# of Institutions
264Shares Held
49.2MCall Options Held
118KPut Options Held
63.7K-
Black Rock Inc. New York, NY8.01MShares$190 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.2MShares$124 Million0.0% of portfolio
-
Doma Perpetual Capital Management LLC Miami, FL2.7MShares$64.2 Million23.38% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.16MShares$51.4 Million0.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.14MShares$50.8 Million0.08% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $1.09B
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...